Skip to content

Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity

The Effect of Synbiotic on Intestinal Microbiota and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) on Obesity

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04642482
Enrollment
16
Registered
2020-11-24
Start date
2019-09-24
Completion date
2020-09-01
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Obesity

Keywords

Intestinal Microbiota, Probiotic, Insulin Resistance, Obesity

Brief summary

Background : There is a plausible relationship between microbial gut and insulin resistance. Intervention to prevent insulin resistance by modifying the microbial gut has been proposed but limited studies demonstrates the expected impact. One of the possible way to manipulate the microbial gut is the administration of synbiotic (prebiotic and probiotic). Objective : This study aim to address the impact of synbiotic administration to the microbial gut and insulin resistance. Brief Methodology : A Quasi Experimental study with multiple arms is conducted to healthy participants. All subjects will undergo a microbial gut taxonomic analysis using faecal sample and blood examination to determine the insulin resistance status (using Homeostatic Model Assessment for Insulin Resistance/HOMA-IR approach). Synbiotic will be given to intervention arm and active comparator will use maltodextrin. Repeated measurement will be conducted after 8 weeks and 12 weeks from the day of administration. Hypothesis : A superiority trial hypothesis is applied, assuming that the synbiotic group will demonstrates higher variety of microbial gut and lower HOMA-IR level

Detailed description

Study Location : This study will recruit the healthy participants from the university Target Population: Healthy Participants General Study Design : Quasi Experimental study with a comparator Sample Size calculation : Difference between two means of HOMA IR from pilot data (7) and standard deviation 2.9, with 5% Type I error, and 80% Power yielded a total of 16 participants for two arms Management of Sample: 1. Faecal Sample handling 1. Patient should undergo 8 hours of fasting prior to faecal examination 2. DNA Extraction 3. Lysate preparation and centrifuge faecal sample 4. Mixing lysate with sample 5. Column wash 6. DNA elution 7. DNA storing 8. DNA sequencing and analysis 9. taxonomical analysis 2. Fasting blood glucose 1. Patient should undergo 8 hours of fasting prior to Fasting blood glucose 2. Blood is taken from cubital vein 3. Spectrometry is conducted based on the NADPH formation from the equation below D-glucose+ATP -----\> Glucose-6-phospate+ADP Glucose-6-phospate+NAD ---- G-6-PDH ---\> D-Gluconate-6 phospate+NADH+H 3. Insulin level 1. Centrifuge blood to obtain the serum 2. The monoclonal anti-insulin antibody is given to the serum 3. detection is based on the anti-insulin antibody and insulin complex formation 4. Homeostatic Model Assessment for Insulin Resistance/ HOMA-IR value is calculated from glucose level multiply by insulin level and divided by 405. Protection for adverse event 1. All subjects are given the consent regarding the potential harm of synbiotic administration 2. All subjects will follow the protocol of reporting the any adverse event (most likely, severe constipation) 3. All subjects will be treated accordingly and hospitalisation if needed. Statistical Analysis 1. General Analysis : Intention To Treat (ITT) 2. Propensity Score Matching will be conducted prior to intervention 3. A repeated measure ANOVA will be performed, whereas Generalized Linear Mixed Model treating the intervention as dummy variable will be performed if ANOVA assumptions can not be fulfilled.

Interventions

DIETARY_SUPPLEMENTSynbiotic (Rillus)

Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.

DRUGPlacebo

Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.

Sponsors

Hasanuddin University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The participants receive the synbiotic in the form of fine powder and taken orally and packed with similar packages. Care provider (Research assistants) distribute the unlabeled formulation to the participants. Outcome assessors (laboratory technician) will not be informed regarding the allocation. Investigators are blinded from allocation and will not be informed until the final analysis. Only the statistician will perform and aware of the allocation. A propensity matching score (PSM) is preferred to allocate the participants.

Intervention model description

A multiple-arm study involves three different groups receiving synbiotic (probiotic + prebiotic) and placebo. Observation of intestinal microbiota and insulin resistance is observed in repeated measurement

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age above 18 years old 2. Not receive antibiotic prescription within the last 6 months

Exclusion criteria

1. Taking medication that alters the blood sugar 2. Taking probiotic or synbiotic product (such as yogurt) 3. Participant who do not take the synbiotic intervention for more than 3 days consecutively 4. incomplete follow up examination results 5. Develop adverse effect

Design outcomes

Primary

MeasureTime frameDescription
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)Changes of HOMA IR value from baseline to 8 weeksa value representing the insulin resistance yielded by multiplying the blood glucose value and insulin value, then divided by 405 (considering the unit of values are in mg/dL not mmol)

Other

MeasureTime frameDescription
Abundance-based Coverage Estimator (ACE) Index of Faecal SamplePrior to intervention (Time 0), 8 weeks after Time 0, and 12 weeks after Time 0This index defined as the sum of the probabilities of the observed species. The ACE method divides observed frequencies into abundant and rare groups. The abundant species are those with more than 10 individuals in the sample, and the rare species are those with fewer than 10 individuals
Shannon Index of Faecal SamplePrior to intervention (Time 0), 8 weeks after Time 0, and 12 weeks after Time 0The Shannon diversity index to a value between 0 and 1. Lower values indicate more diversity of microbial gut while higher values indicate less diversity.

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026